Withdrawal of application for EMA change to the marketing authorisation of pazopanib

GlaxoSmithKline Research & Development has officially notified the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application to extend the use of pazopanib (Votrient) to include maintenance treatment in women with ovarian, fallopian tube or primary peritoneal cancer whose disease improved or remained stable after first-line chemotherapy. Votrient is a cancer medicine that contains the active substance pazopanib. It has been authorised since June 2010 for treating advanced renal-cell carcinoma and certain forms of soft-tissue sarcoma. Read more here.